×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABUS – arbutus biopharma corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/6
08:28 am
abus
Here's Why Arbutus (ABUS) Surged in Q3 [Yahoo! Finance]
Low
Report
Here's Why Arbutus (ABUS) Surged in Q3 [Yahoo! Finance]
12/3
08:13 am
abus
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors [Yahoo! Finance]
Medium
Report
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors [Yahoo! Finance]
12/3
08:00 am
abus
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
Low
Report
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
11/26
07:30 am
abus
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Medium
Report
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
11/20
07:33 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
11/18
08:09 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/15
11:11 am
abus
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon [Yahoo! Finance]
Low
Report
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon [Yahoo! Finance]
11/15
11:11 am
abus
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B [Yahoo! Finance]
Medium
Report
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
07:30 am
abus
arbutus biopharma corporation
MISS
Report
-1.3%
arbutus biopharma corporation
8/1/2024
07:30 am
abus
arbutus biopharma corporation
MISS
Report
0.5%
arbutus biopharma corporation
5/2/2024
07:30 am
abus
arbutus biopharma corporation
IN-LINE
Report
-0.4%
arbutus biopharma corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/6
06:01 am
abus
Form EFFECT Arbutus Biopharma Corp
Low
Report
Form EFFECT Arbutus Biopharma Corp
11/15
11:03 am
abus
Form 8-K Arbutus Biopharma Corp For: Nov 15
Medium
Report
Form 8-K Arbutus Biopharma Corp For: Nov 15
11/14
08:41 am
abus
Form SC 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP
Low
Report
Form SC 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP
11/6
04:54 pm
abus
Form S-3 Arbutus Biopharma Corp
Medium
Report
Form S-3 Arbutus Biopharma Corp
11/6
04:03 pm
abus
Form 10-Q Arbutus Biopharma Corp For: Sep 30
Medium
Report
Form 10-Q Arbutus Biopharma Corp For: Sep 30
11/6
07:32 am
abus
Form 8-K Arbutus Biopharma Corp For: Nov 06
Low
Report
Form 8-K Arbutus Biopharma Corp For: Nov 06
10/15
08:27 am
abus
Form 8-K Arbutus Biopharma Corp For: Oct 15
Medium
Report
Form 8-K Arbutus Biopharma Corp For: Oct 15
10/11
04:08 pm
abus
Form 8-K Arbutus Biopharma Corp For: Oct 11
Low
Report
Form 8-K Arbutus Biopharma Corp For: Oct 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/20
Arbutus receives clearance to initiate early-stage AB-729 trial; shares up 8% premarket [Seeking Alpha]
32.6%
6/17 Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. 24.7%
2/10 Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer 20.6%
10/4 Arbutus Biopharma Corp (NASDAQ: ABUS) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. 13.3%
2/27 Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results 10.7%
11/4 We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate [Yahoo! Finance News] 5.1%
5/20 Form 8-K Arbutus Biopharma Corp For: May 20 4.9%
7/3 Form 8-K Arbutus Biopharma Corp For: Jul 02 4.2%
7/12 Form 4 Arbutus Biopharma Corp For: Jul 10 Filed by: SVF Holdings (UK) LLP 4.0%
8/5 Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.1%
6/17 Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D. 24.7%
2/10 Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer 20.6%
10/4 Arbutus Biopharma Corp (NASDAQ: ABUS) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. 13.3%
2/27 Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results 10.7%
11/4 We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate [Yahoo! Finance News] 5.1%
5/20 Form 8-K Arbutus Biopharma Corp For: May 20 4.9%
7/3 Form 8-K Arbutus Biopharma Corp For: Jul 02 4.2%
7/12 Form 4 Arbutus Biopharma Corp For: Jul 10 Filed by: SVF Holdings (UK) LLP 4.0%
8/5 Arbutus Biopharma Corporation (ABUS) CEO William Collier on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 3.1%
TOP News Decliners
3/26
Form 8-K Arbutus Biopharma Corp For: Mar 26
-47.4%
10/3 Form 8-K Arbutus Biopharma Corp For: Oct 03 -28.7%
10/7 Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target lowered by analysts at B. Riley from $7.00 to $3.00. They now have a "buy" rating on the stock. -16.0%
7/15 Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 [Seeking Alpha] -12.5%
7/18 Form 8-K Arbutus Biopharma Corp For: Jul 15 -11.3%
8/9 Form 8-K Arbutus Biopharma Corp For: Aug 09 -8.5%
5/13 Arbutus to Present at Upcoming May 2019 Conferences -7.9%
3/6 Form 10-K/A Arbutus Biopharma Corp For: Dec 31 -7.1%
5/28 Form 8-K Arbutus Biopharma Corp For: May 22 -6.9%
9/26 Arbutus to Participate in Upcoming Investor Conferences -6.3%
10/3 Form 8-K Arbutus Biopharma Corp For: Oct 03 -28.7%
10/7 Arbutus Biopharma Corp (NASDAQ: ABUS) had its price target lowered by analysts at B. Riley from $7.00 to $3.00. They now have a "buy" rating on the stock. -16.0%
7/15 Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 [Seeking Alpha] -12.5%
7/18 Form 8-K Arbutus Biopharma Corp For: Jul 15 -11.3%
8/9 Form 8-K Arbutus Biopharma Corp For: Aug 09 -8.5%
5/13 Arbutus to Present at Upcoming May 2019 Conferences -7.9%
3/6 Form 10-K/A Arbutus Biopharma Corp For: Dec 31 -7.1%
5/28 Form 8-K Arbutus Biopharma Corp For: May 22 -6.9%
9/26 Arbutus to Participate in Upcoming Investor Conferences -6.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: